Semaglutide Capsules (500mcg) 25 Count

Oral Semaglutide represents a transformative advancement as the first orally bioavailable glucagon-like peptide-1 (GLP-1) receptor agonist. This 31-amino acid synthetic peptide shares 94% sequence homology with endogenous human GLP-1(7-37) and incorporates three strategic molecular modifications: an aminoisobutyric acid (Aib) substitution at position 8 for DPP-4 resistance, a lysine-to-arginine substitution at position 34 for enhanced proteolytic stability, and a C-18 fatty di-acid chain conjugated at position 26 for high-affinity albumin binding. These modifications extend the elimination half-life from ~2 minutes (native GLP-1) to ~1 week, enabling once-daily oral administration.

The oral formulation overcomes the traditional barrier to peptide oral delivery through co-formulation with sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), an absorption enhancer that facilitates stomach-specific transcellular absorption. SNAC creates localized pH buffering (pH ~6-7), protects from gastric enzymatic degradation, and enables transient membrane permeability enhancement without disrupting tight junction complexes. The PIONEER phase III program (12 trials, 9,542 patients) established oral semaglutide's efficacy across the type 2 diabetes spectrum, while the OASIS trial validated higher doses (25-50mg) for obesity management, demonstrating 15.1% mean weight loss at 68 weeks.

Cryo-EM structures (3.0 Å resolution, PDB: 7KI0) reveal semaglutide adopts a binding pose highly similar to native GLP-1, with the N-terminal His-Aib dipeptide engaging the transmembrane domain and C-terminal helix interacting with the extracellular domain. The C-18 fatty acid extends away from the receptor binding interface, confirming albumin-binding and receptor-activation functions are structurally independent.

This research-grade peptide is provided at >98% purity for investigations of GLP-1 receptor pharmacology, oral peptide delivery, SNAC absorption enhancement, metabolic disease mechanisms, and class B GPCR structural biology.

This product is intended strictly for research purposes and is not for human or veterinary use.